Szukaj

42 Result(s)
Sortuj według

Retinal health

Retinal health

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in Retinal Health.
Championing novel science

Championing novel science

Dr. Vikas Mohan Sharma announces FDA fast-track designation for BI 1358894 as potential treatment for Borderline Personality Disorder.
Advancing regenerative medicine

Advancing regenerative medicine

Strategic partnerships play a key role in helping the company accelerate the next generation of breakthroughs.
Światowy Dzień Chorób Rzadkich 2021

Światowy Dzień Chorób Rzadkich 2021

Rzadkie, ale nie zapomniane: dlaczego wsparcie medyczne dla około 30 milionów osób w UE cierpiących na choroby rzadkie1 jest nie do przecenienia
More Health Overview

More Health Overview

Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
Antibody therapeutics business partnering PetMedix

Antibody therapeutics business partnering PetMedix

Combining PetMedix’ expertise in veterinary biotherapeutic technology with Boehringer Ingelheim’s long experience and innovation in human antibody discovery and development provides a unique opportunity for the partners.
Stem cells a new frontier

Stem cells a new frontier

Stem cells may be a game changer for the development of new veterinary treatments. Read this story to find out why.
Our Partnering Culture

Our Partnering Culture

We embrace the power of partnerships and alliances to find even more breakthrough therapies that change lives.
Contact us

Contact us

Find all our contact information here about our BD&L team.
Być niezależnym

Być niezależnym

Kultura korporacyjna Boehringer Ingelheim opiera się na wartościach, które są stosowane od momentu założenia firmy w 1885 roku.
Women in STEM 2022

Women in STEM 2022

Meet three of Boehringer Ingelheim's female scientists and learn why and how women are making a difference in STEM.